Le Lézard20h
Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...
UroToday7h
ASCO GU 2025: Age-Related Efficacy and Safety of Darolutamide + ADT and Docetaxel in Patients with mHSPC: A Subgroup Analysis of ARASENS
Patients with mHSPC benefited from darolutamide + ADT + docetaxel irrespective of age (<75 years and ≥75 years), with consistent improvements in overall survival, time to mCRPC, and time to initiation ...
UroToday13h
ASCO GU 2025: Darolutamide + ADT in Patients with mHSPC by Disease Volume: Subgroup Analysis of the Phase 3 ARANOTE Trial
GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Fred Saad discussing a subgroup analysis of the phase 3 ARANOTE trial assessing darolutamide + ADT in patients with ...